30 January 2015 |
AIM: RENE |
Director Share Purchases
Guildford, UK, 30 January 2015: ReNeuron Group plc (AIM: RENE), a leading UK-based stem cell therapy company, was informed on 29 January 2015 that two of its Directors acquired ordinary shares of 1p each ("Ordinary Shares") as follows:
|
|
|
|
|
Interest after purchase |
|
|
Director |
Title |
Number of Ordinary Shares acquired on 29 January 2015 |
Price per share |
Number of Ordinary Shares |
% of total issued share capital |
|
Olav Hellebø |
Chief Executive Officer
|
322,778 |
3.1p |
322,778 |
0.02% |
|
Michael Hunt |
Chief Financial Officer
|
161,556 |
3.1p |
1,508,471 |
0.08% |
The issued share capital of the Company is 1,788,827,700 1p ordinary shares.
Enquiries:
|
ReNeuron |
+44 (0) 1483 302560 |
|
Olav Hellebø, Chief Executive Officer Michael Hunt, Chief Financial Officer |
|
|
|
|
|
Buchanan |
+44 (0) 20 7466 5000 |
|
Mark Court, Sophie Cowles, Stephanie Watson |
|
|
|
|
|
Cenkos Securities |
+44 (0) 20 7397 8900 |
|
Stephen Keys, Dr Christopher Golden (NOMAD and Broker) |
|
|
Andy Roberts (Sales) |
|
About ReNeuron
ReNeuron is a leading, clinical-stage cell therapy development business. Based in the UK, its primary objective is the development of novel cell-based therapies targeting areas of significant unmet or poorly met medical need.
ReNeuron has used its unique stem cell technologies to develop cell-based therapies for significant disease conditions where the cells can be readily administered "off-the-shelf" to any eligible patient without the need for additional immunosuppressive drug treatments. The Company's therapeutic candidates for stroke disability and critical limb ischaemia are in clinical development and its cell-based treatment for blindness-causing diseases of the retina is currently in pre-clinical development.
ReNeuron is also advancing a proprietary platform technology to exploit nanoparticles (exosomes) secreted by stem cells as potential new drug candidates targeting indications in tissue repair, fibrosis and cancer.
ReNeuron's shares are traded on the London AIM market under the symbol RENE.L. Further information on ReNeuron and its products can be found at www.reneuron.com.
